Background: Breast cancer is the most common malignancy in females worldwide. Several etiological factors including environmental factors have been recognized for breast cancer. Epstein Barr virus as a viral etiological factor has been proposed. So far, several studies have investigated the relationship between development of breast cancer and Epstein Barr virus, but few have been done in Iran. The aim of this study was to determine whether there was an association between EBV infection and female breast cancer in Iran. Materials and Methods:We analyzed paraffin embedded breast tissue specimens by polymerase chain reaction (PCR) including breast cancer specimens (as case group) and breast fibroadenoma specimens (as control group). PCR was performed to amplify specific sequences of EBV. Results: From 130 cases of breast samples, 67 cases of breast cancer tissues and 41 cases of breast fibroadenoma tissues had adequate quality and quantity of DNA to detect EBV. PCR for EBV was positive in 4 invasive ductal carcinoma specimens (7.3%) and only one of the fibroadenoma specimens (2.4%). No significant association was found between EBV infection and invasive ductal carcinoma (p> 0.05). Also, patient's age and histological grade of IDC were not correlated with EBV infection (p>0.05). Conclusion:We observed no etiologic association between EBV infection and invasive ductal carcinoma of female breast in our regions; however, further studies are required to elucidate this association.

Background: The mortality and morbidity of COVID‐19 disease as well as the lack of a proper medication has forced researchers and clinicians to employ urgent efficient technologies to overcome this current pandemic. In the severe forms of COVID-19, the patients develop a cytokine storm syndrome (CSS) where pro-inflammatory cytokines such as IL-6 and TNF-α play a key role in the development of this serious process. The efficiency of nanomedicines - as efficient immunomodulators - that are synthesized based on nanochelating technology have been proved in the previous studies. In the present study, the therapeutic effect of the combination of BCc1 and Hep-S nanomedicines on hospitalized COVID-19 patients was evaluated.Method: Laboratory-confirmed moderate COVID-19 patients at Masih Daneshvari Hospital were enrolled to participate in a randomized, double-blind, placebo-controlled study in two separate groups: combination of BCc1 and Hep-S (N=62) (treatment) or placebo (N=60) (placebo). The primary outcome of the study was evaluating the safety of the nanomedicines combination and its effect on the number of deceased patients, while the secondary outcome was decrease in inflammatory cytokines.Results: The evaluation of blood biochemical indices as well as clinical symptoms showed that adding the combination of BCc1 and Hep-S nanomedicines to the standard protocol of the treatment caused no adverse effects. The results analysis revealed that 28-day consumption of the nanomedicines led to a significant decrease in the mean level of IL-6 cytokine of the patients in the treatment group (p < 0.05). In addition, the patients in the treatment group had lower TNF-α levels compared to those in the control (p > 0.05) and they also showed less need for oxygen therapy. Finally, the number of the deceased patients in the treatment group was 30% lower than that of the control (p > 0.05).Conclusion: The combination of BCc1 and Hep-S, as safe nanomedicines, inhibits IL-6 as a highly important and well-known cytokine in COVID-19 pathophysiology, and presents a promising view for immunomodulation that can manage CSS and reduce mortality rate in COVID19 patients.Trial registration IRCTID, IRCT20170731035423N2. Registered 12 Jun 2020, http://www.irct.ir/ IRCT20170731035423N2.